OMT-111 for Terminal Stage Solid Tumors

A Multi-site, Single Arm, Phase II Clinical Trial, to Evaluate the Efficacy of OMT-111 in Supporting the Treatment of Terminal Stage Solid Tumors

Patients with terminal stage of metastatic non-small cell lung cancer, metastatic triple negative breast cancer, or advanced or metastatic pancreatic adenocarcinoma resisting to standard therapies.

Study Overview

• Status: Unknown
• Conditions: Breast Cancer; Pancreatic Cancer; Lung Cancer
• Intervention / Treatment: Drug: OMT-111

Detailed Description

This is a multi-site, single arm, Phase II study designed to explore the efficacy of OMT-111 in patients with terminal stage solid tumors resistant to standard therapies.

Subjects who voluntarily provide written consent to participate in this study undergo screening tests within 4 weeks prior to the first dose of investigational product. Those who meet the inclusion/exclusion criteria are enrolled in the study.

1 cycle consists of 4 weeks (28 days). Each week consists of 5 days of treatment and 2 days of treatment-free interval (20 days of treatment and 8 days of treatment-free interval per cycle in total). This study is planned to enroll approximately 76 subjects including 42 subjects with lung cancer, 22 subjects with breast cancer, and 12 subjects with pancreatic cancer. Treatment will be provided for 12 cycles (48 weeks). During the study, tests and procedures to evaluate the efficacy and safety will be carried out according to the planned schedule.

• Study Type: Interventional
• Enrollment (Anticipated): 78
• Phase: Phase 2

Contacts and Locations

Study Locations

• Vietnam
  • Hanoi, Vietnam
    • K Hospital
  • Hochiminh city, Vietnam
    • Cho Ray Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Breast Cancer

  1. Female at least 18 years old or older at the time of informed consent
  2. Histologically or cytologically confirmed triple negative ductal adenocarcinoma of breast
  3. Patients who have visceral metastatic lesions not amenable by resection or radiotherapy (e.g., multiple visceral lesions)
  4. ECOG PS (Eastern Cooperative Oncology Group Performance Status): 0-2
  5. Patients with a life expectancy ≥ 12 weeks as judged by the investigator
  6. At least one measurable lesion or evaluable lesion defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

• Pancreatic Cancer

  1. Male or female at least 18 years old or older at the time of informed consent
  2. Histologically or cytologically confirmed adenocarcinoma of pancreas
  3. Patients who have advanced or metastatic lesions not amenable by resection or radiotherapy
  4. ECOG PS (Eastern Cooperative Oncology Group Performance Status) ≤ 2
  5. Patients with a life expectancy ≥ 12 weeks as judged by the investigator
  6. At least one measurable lesion or evaluable lesion defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

• Lung Cancer

  1. Male or female at least 18 years old or older at the time of informed consent
  2. Histologically or cytologically confirmed carcinoma of the lung (small cell lung cancer not included)
  3. Patients who have unresectable metastatic lesion
  4. ECOG PS (Eastern Cooperative Oncology Group Performance status) ≤ 2
  5. Patients with a life expectancy ≥ 12 weeks as judged by the investigator
  6. At least one measurable lesion or evaluable lesion defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

Exclusion Criteria:

• Breast Cancer

  1. History of malignancy other than metastatic triple negative breast cancer within 5 years prior to the first dose of investigational product (however, patients with effectively treated skin cancer, thyroid cancer, and carcinoma in situ that has been in complete remission for at least 3 years and thus considered cured by the investigator are eligible)
  2. Uncontrolled CNS metastasis (however, patients with treated and stable brain metastasis (radiographically stable for at least 30 days without steroids) are eligible)
  3. Primary cancer-related complications potentially requiring urgent surgery as judged by the investigator
  4. Grade ≥ 3 active infection requiring intravenous antibiotics per NCI-CTCAE version 5.0

  5. History of one or more of the following cardiovascular diseases

     • Cerebrovascular disease, unstable angina, or myocardial infarction within 6 months prior to the screening visit (Visit 1)
     • Congestive heart failure corresponding to New York Heart Association (NYHA) Class III or above (see Appendix 1. NYHA Classification)
     • Serious cardiac arrhythmia not controlled with medication or clinically significant cardiovascular abnormality as judged by the investigator
     • QTc > 480 msec (Fredericia's formula) during 12-lead ECG at screening visit (Visit 1)
  6. Pregnant women, breast-feeding women or women with a positive pregnancy test at screening visit (Visit 1)
  7. Renal impairment or chronic renal failure patient requiring hemo- or peritoneal dialysis
  8. Previous treatment with the investigational product
  9. Treatment with other investigational product within 30 days prior to the first dose of the investigational product
  10. Unable to come to the site hospital on a daily basis for investigational product administration
  11. Patients who are otherwise considered to be ineligible for this study based on investigator's judgment.

• Pancreatic Cancer

  1. History of malignancy other than advanced or metastatic pancreatic adenocarcinoma within 5 years prior to the first dose of investigational product (however, patients with effectively treated skin cancer, thyroid cancer, and carcinoma in situ that has been in complete remission for at least 3 years and thus considered cured by the investigator are eligible)
  2. Uncontrolled CNS metastasis (however, patients with treated and stable brain metastasis (radiographically stable for at least 30 days without steroids) are eligible)
  3. Primary cancer-related complication potentially requiring urgent surgery as judged by the investigator
  4. Grade ≥ 3 active infection requiring intravenous antibiotics per NCI-CTCAE version 5.0

  5. History of one or more of the following cardiovascular diseases

     • Cerebrovascular disease, unstable angina, or myocardial infarction within 6 months prior to the screening visit (Visit 1)
     • Congestive heart failure corresponding to New York Heart Association (NYHA) Class III or above (see Appendix 1. NYHA Classification)
     • Serious cardiac arrhythmia not controlled with medication or clinically significant cardiovascular abnormality as judged by the investigator
     • QTc > 480 msec (Fredericia's formula) during 12-lead ECG at screening visit (Visit 1)
  6. Pregnant women, breast-feeding women or women with a positive pregnancy test at screening visit (Visit 1)
  7. Renal impairment or chronic renal failure patient requiring hemo- or peritoneal dialysis
  8. Previous treatment with the investigational product
  9. Treatment with other investigational product within 30 days prior to the first dose of the investigational product
  10. Unable to come to the site hospital on a daily basis for investigational product administration
  11. Patients who are otherwise considered to be ineligible for this study based on investigator's judgment

• Lung Cancer

  1. History of malignancy other than metastatic non-small cell lung cancer within 5 years prior to the first dose of investigational product (however, patients with effectively treated skin cancer, thyroid cancer, and carcinoma in situ that has been in complete remission for at least 3 years and thus considered cured by the investigator are eligible)
  2. Uncontrolled CNS metastasis (however, patients with treated and stable brain metastasis (radiographically stable for at least 30 days) are eligible)
  3. Primary cancer-related complication potentially requiring urgent surgery as judged by the investigator
  4. Grade ≥ 3 active infection requiring intravenous antibiotics per NCI-CTCAE version 5.0

  5. History of one or more of the following cardiovascular diseases

     • Cerebrovascular disease, unstable angina, or myocardial infarction within 6 months prior to the screening visit (Visit 1)
     • Congestive heart failure corresponding to New York Heart Association (NYHA) Class III or above (see Appendix 1. NYHA Classification)
     • Serious cardiac arrhythmia not controlled with medication or clinically significant cardiovascular abnormality as judged by the investigator
     • QTc > 480 msec (Fredericia's formula) during 12-lead ECG at screening visit (Visit 1)
  6. Pregnant women, breast-feeding women or women with a positive pregnancy test at screening visit (Visit 1)
  7. Renal impairment or chronic renal failure patient requiring hemo- or peritoneal dialysis
  8. Previous treatment with the investigational product
  9. Treatment with other investigational product within 30 days prior to the first dose of the investigational product
  10. Unable to come to the site hospital on a daily basis for investigational product administration
  11. Patients who are otherwise considered to be ineligible for this study based on investigator's judgment

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Open label single arm; 1 cycle consists of 4 weeks (28 days). Each week consists of 5 days of treatment and 2 days of treatment-free interval	Drug: OMT-111; Pre-filled Syringe; Other Names: OMT-110

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Disease Control Rate (DCR)	Every two cycles (8 weeks)	From the start of treatment to 48 weeks.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective Response Rate (ORR)	Every two cycles (8 weeks)	From the start of treatment to 48 weeks.
Duration of Response (DoR)	Every two cycles (8 weeks)	From the start of treatment to 48 weeks.
Progression-Free Survival (PFS)	Every two cycles (8 weeks)	From the start of treatment to 48 weeks.
18F-FDG- PET/CT (SUVmean and SUVmax)	Every two cycles (8 weeks)	From the start of treatment to 48 weeks.

Collaborators and Investigators

• Sponsor: MetiMedi Pharmaceuticals
• Investigators: Study Director: Soobong Park, MetiMedi Pharmaceuticals

Study record dates

Study Major Dates

• Study Start (Anticipated): October 1, 2020
• Primary Completion (Anticipated): June 30, 2022
• Study Completion (Anticipated): October 1, 2022

Study Registration Dates

• First Submitted: August 12, 2020
• First Submitted That Met QC Criteria: August 18, 2020
• First Posted (Actual): August 20, 2020

Study Record Updates

• Last Update Posted (Actual): September 9, 2020
• Last Update Submitted That Met QC Criteria: September 8, 2020
• Last Verified: September 1, 2020

More Information

Terms related to this study

• Other Study ID Numbers: Metimedi-202

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No